A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Colon Cancer Who Are Candidates for Resection of Primary Tumour
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2016
Price : $35 *
At a glance
- Drugs Enadenotucirev (Primary)
- Indications Colon cancer
- Focus Pharmacokinetics
- Acronyms MOA
- Sponsors PsiOxus Therapeutics
- 08 Sep 2016 Status changed from active, no longer recruiting to completed.
- 31 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 23 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.